Determination Of YKL-40 In Patients With Lung Cancer And Its Clinical Significance

Lung cancer is a kind of tumor with short life. But it is very difficult to diagnosed early in the clinical. YKL-40 is expressed and secreted by several types of solid tumors. The exact function of YKL-40 in cancer diseases is unknown and is an important objective of future studies. YKL-40 exhibits growth factor activity for cells involved in tissue remodeling processes. YKL-40 may have a role in cancer cell proliferation, survival, and invasiveness, in the inflammatory process around the tumor, angiogenesis, and remodeling of the extracellular matrix. The present retrospective clinical studies of patients with several different types of primary or advanced solid tumors suggest that serum concentration of YKL-40 may be a new biomarker in cancer patients. Elevated serum YKL-40 is found in a subgroup of patients with different types of solid tumors, including several types of adenocarcinomas, glioblastoma, and melanoma and so on. It is unknown whether the serum concentration of YKL-40 could be a new biomarker in lung cancer patients at home, so this test is used as to check it.Objective To study the serum concentration of YKL-40 in patients with lung cancer and judge whether this detection has clinical significance or not.Methods Serum concentration of YKL-40 were measured by using an enzyme-linked immunoadsorbent assay (ELISA) in 12 person with fine physical examination(control group) and 60 patients with lung cancer(lung cancer group) and 15 patients with lung beingn diseases (lung benign disease group). All of patients with lung cancer were confirmed by histopathology or cytopathology and did not have any anticancer treatment.Results Serum concentration of YKL-40 in lung cancer group (161.88±95.65ng/ml were significantly higher than those in control group (54.56±18.86ng/ml).The differences between the lung benign group (98.40±36.28ng/ml) and the lung cancer group reached the statistical significance, P<0.05. There were significantly differences among the primary lung cancer group (116.77±39.15 ng/ml) and the metastatic lung cancer group (267.14±106.28 ng/ml)Conclusion The serum concentration of YKL-40 were significantly elevated in patients with lung cancer and so could be possibly used in clinical diagnosis and differential diagnosis of lung cancer as a new tumor biomarker.